

**Supplementary Table 4:**  
**Number and Percent of Participants Missing Entry and/or**  
**Exit HRSD Used for Last Observation Carried Forward Analyses**

	<b>#/(%) with Missing Entry HRSD</b>	<b>#/(%) with Missing Exit HRSD</b>
<b>Step 1 (N=3,110)</b>	0 (0%)	926 (29.8%)
<b>Step 2 (N=1,134)</b>	168 (14.8%)	304 (26.8%)
<b>Switch strategy (N=620)</b>	90 (14.5%)	183 (29.5%)
Bupropion (N=190)	34	58
Sertraline (N=198)	27	56
Venlafaxine (N=192)	24	56
Cognitive Therapy (N=40)	5	13
<b>Augmentation strategy (N=514)</b>	78 (15.2%)	121 (23.5%)
Bupropion (N=216)	35	58
Buspirone (N=225)	37	52
Cognitive Therapy (N=73)	6	11
<b>Step 3 (N=325)</b>	42 (12.9%)	78 (24%)
<b>Level 2A (N=28)</b>	3	6
Bupropion (N=12)	3	2
Venlafaxine (N=16)	0	4
<b>Level 3 (N=297)</b>	39	72
<b>Switch strategy (N=186)</b>	26	49
Nortriptyline (N=92)	11	23
Mirtazapine (N=94)	15	26
<b>Augmentation strategy (N=111)</b>	13	23
<b>Lithium (N=58)</b>	9	13
Bupropion SR (N=17)	3	2
Citalopram (N=22)	5	6
Sertraline (N=11)	1	3
Venlafaxine XR (N=8)	0	2
<b>T3 (N=53)</b>	4	10
Bupropion SR (N=6)	1	0
Citalopram (N=26)	1	7
Sertraline (N=8)	1	1
Venlafaxine XR (N=13)	1	2

<b>Step 4 (N=106)</b>	<b>15 (14.2%)</b>	<b>22 (20.8%)</b>
Level 3 (N=16)	3	3
Tranlycypromine (N=43)	7	10
Venlafaxine XR/mirtazapine (N=47)	5	9